EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of the C-PLAN Index in Metastatic Renal Cell Carcinoma Treated with Nivolumab

Gökhan Şahin iD, Caner Acar iD, Haydar Çağatay Yüksel iD, Salih Tünbekici, Fatma Pınar Açar, Erhan Gökmen, Burçak Karaca

Journal of Clinical Medicine · 25.03.2025 · 14 (7) · 2217

DOI: 10.3390/jcm14072217 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.03.2025. Verfasst von Gökhan Şahin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 İzmir, Türkiye. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KSK Danışmanlık (Ksk Dan. Tıbbi Araşt. Tur. Org. Eğt. Ve Tic. Ltd. Şti.), İstanbul, Turkey.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Nivolumab has been shown to be an effective treatment for metastatic renal cell carcinoma (mRCC); however, patient responses vary considerably. The objective of this study is to evaluate the prognostic value of the C-PLAN index in predicting survival outcomes for patients with mRCC treated with nivolumab.

Methods

This retrospective cohort study included 81 mRCC patients previously treated with tyrosine kinase inhibitors who subsequently received nivolumab. The C-PLAN index, which includes C-reactive protein, performance status, lactate dehydrogenase, albumin, and derived neutrophil-to-lymphocyte ratio, was used to classify patients into “good” and “poor” prognostic groups.

Results

The median overall survival (OS) was 22 months, and the median progression-free survival (PFS) was 6.7 months. Patients in the “poor” C-PLAN group exhibited significantly shorter OS and PFS than those in the “good” group (median OS: 13 vs. 31 months, p = 0.003; median PFS: 3 vs. 10 months, p = 0.007). The C-PLAN index was identified as an independent predictor of both OS (HR = 1.19, 95% CI: 1.11–3.43, p = 0.020) and PFS (HR = 1.71, 95% CI: 1.04–2.78, p = 0.032) in multivariate analysis.

Conclusions

These findings suggest that the C-PLAN index may serve as a valuable prognostic tool, offering insights into survival outcomes for patients undergoing nivolumab therapy. Further prospective and multicenter studies are warranted to validate its clinical utility.

Schlagwörter

Stichwörter der Autor:innen

C-PLAN indexmetastatic renal cell carcinomanivolumaboverall survivalprognostic biomarkerprogression-free survival

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine, Ege University, 35100 İzmir, Türkiye.

ORCID-Profile: Gökhan Şahin, Caner Acar, Haydar Çağatay Yüksel

Förderung

  • KSK Danışmanlık (Ksk Dan. Tıbbi Araşt. Tur. Org. Eğt. Ve Tic. Ltd. Şti.), İstanbul, Turkey

Zitieren

APA

Şahin, G., Acar, C., Yüksel, H. Ç., Tünbekici, S., Açar, F. P., Gökmen, E., & Karaca, B. (2025). Prognostic Value of the C-PLAN Index in Metastatic Renal Cell Carcinoma Treated with Nivolumab. Journal of Clinical Medicine, 14(7), 2217. https://doi.org/10.3390/jcm14072217

Vancouver

Şahin G, Acar C, Yüksel HÇ, Tünbekici S, Açar FP, Gökmen E, et al. Prognostic Value of the C-PLAN Index in Metastatic Renal Cell Carcinoma Treated with Nivolumab. Journal of Clinical Medicine. 2025;14(7):2217. doi:10.3390/jcm14072217

BibTeX
@article{ahin2025,
  author = {Şahin, Gökhan and Acar, Caner and Yüksel, Haydar Çağatay and Tünbekici, Salih and Açar, Fatma Pınar and Gökmen, Erhan and Karaca, Burçak},
  title = {Prognostic Value of the C-PLAN Index in Metastatic Renal Cell Carcinoma Treated with Nivolumab},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {7},
  pages = {2217},
  doi = {10.3390/jcm14072217}
}
Kostenlos starten →